Bevacizumab preferred option in mCRC

  • PDF / 113,796 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 73 Downloads / 289 Views

DOWNLOAD

REPORT

1173-5503/10/0671-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 9 Feb 2013 No. 671

1

Data Loading...

Recommend Documents
Bevacizumab + capecitabine not cost effective in mCRC

162 48 111KB

Ferric carboxymaltose preferred option in IBD-associated iron deficiency anaemia

180 91 166KB

Immunotherapy in Patients with mCRC

190 94 13MB

Bevacizumab

153 109 138KB

Bevacizumab

161 9 137KB

Bevacizumab

128 24 180KB

Bevacizumab

127 49 137KB

Bevacizumab

146 121 165KB

Bevacizumab

160 97 167KB

Bevacizumab

159 61 167KB

Bevacizumab

121 25 166KB

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

128 50 702KB